[go: up one dir, main page]

BRPI0917147B8 - composto ou sal deste, uso de um composto ou sal deste, e, processo para fabricar um composto - Google Patents

composto ou sal deste, uso de um composto ou sal deste, e, processo para fabricar um composto

Info

Publication number
BRPI0917147B8
BRPI0917147B8 BRPI0917147A BRPI0917147A BRPI0917147B8 BR PI0917147 B8 BRPI0917147 B8 BR PI0917147B8 BR PI0917147 A BRPI0917147 A BR PI0917147A BR PI0917147 A BRPI0917147 A BR PI0917147A BR PI0917147 B8 BRPI0917147 B8 BR PI0917147B8
Authority
BR
Brazil
Prior art keywords
compound
salt
making
compounds
alzheimer
Prior art date
Application number
BRPI0917147A
Other languages
English (en)
Inventor
Swahn Britt-Marie
Ruda Katinka
Anders Nilsson Nils
Magnus Schou Per
JOHNSTRÖM Peter
Björk Seth
Delisser Vern
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0917147A2 publication Critical patent/BRPI0917147A2/pt
Publication of BRPI0917147B1 publication Critical patent/BRPI0917147B1/pt
Publication of BRPI0917147B8 publication Critical patent/BRPI0917147B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

composto ou sal deste uso de um composto ou sal deste, e, processo para fabricar um composto. a presente invenção diz respeito a novos derivados que são adequados como percursores para compostos que são úteis para formação de imagem de depósitos de amilóide em pacientes vivos, as suas composições métodos de uso e processos para fabricar tais componentes. os compostos que derivam destes precursores dão úteis nos métodos de formação de imagem de depósitos de amilóide no cérebro in vivo para permitir diagnóstico anterior á morte da doença de alzheimer pela tomografia de emissão de pósitron (pet) assi, como medir a eficácia clínica de agentes terapêuticos para a doença de alzheimer. além disso, a presente invenção também divulga os compostos precursores na forma cristalina.
BRPI0917147A 2008-08-29 2009-08-28 composto ou sal deste, uso de um composto ou sal deste, e, processo para fabricar um composto BRPI0917147B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9285108P 2008-08-29 2008-08-29
US61/092851 2008-08-29
PCT/SE2009/050972 WO2010024769A1 (en) 2008-08-29 2009-08-28 New benzofurans suitable as precursors to compounds that are useful for imaging amyloid deposits

Publications (3)

Publication Number Publication Date
BRPI0917147A2 BRPI0917147A2 (pt) 2015-11-17
BRPI0917147B1 BRPI0917147B1 (pt) 2020-09-15
BRPI0917147B8 true BRPI0917147B8 (pt) 2021-05-25

Family

ID=41721733

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917147A BRPI0917147B8 (pt) 2008-08-29 2009-08-28 composto ou sal deste, uso de um composto ou sal deste, e, processo para fabricar um composto

Country Status (22)

Country Link
US (3) US8193363B2 (pt)
EP (1) EP2328891B1 (pt)
JP (1) JP5613669B2 (pt)
KR (1) KR101648848B1 (pt)
CN (3) CN104478862B (pt)
AR (2) AR073230A1 (pt)
AU (1) AU2009286176B2 (pt)
BR (1) BRPI0917147B8 (pt)
CA (1) CA2735497C (pt)
CL (1) CL2011000420A1 (pt)
CO (1) CO6341628A2 (pt)
EA (1) EA019093B1 (pt)
EC (1) ECSP11010850A (pt)
ES (1) ES2627769T3 (pt)
IL (1) IL211188A0 (pt)
MX (1) MX2011001918A (pt)
NZ (1) NZ591446A (pt)
PE (1) PE20110393A1 (pt)
TW (1) TW201014848A (pt)
UY (1) UY32076A (pt)
WO (1) WO2010024769A1 (pt)
ZA (1) ZA201102284B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193363B2 (en) * 2008-08-29 2012-06-05 Astrazeneca Ab Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits
JP5825608B2 (ja) * 2010-08-06 2015-12-02 国立大学法人京都大学 ピリジルベンゾフラン誘導体
US10098859B2 (en) 2012-09-05 2018-10-16 Amri Ssci, Llc Cocrystals of p-coumaric acid
EP2767532B1 (en) 2012-12-21 2016-07-13 National Institutes for Quantum and Radiological Science and Technology Novel compound for imaging tau protein accumulated in the brain
US10913736B2 (en) 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
US20180344881A1 (en) * 2015-11-20 2018-12-06 Navidea Biopharmaceuticals, Inc. Formulations for 2-heteroaryl substituted benzofurans
TWI903327B (zh) 2018-05-09 2025-11-01 香港商新旭生技股份有限公司 雜芳基化合物及其用途
KR20220100921A (ko) 2019-11-13 2022-07-18 아프리노이아 테라퓨틱스 리미티드 타우 단백질 응집체를 분해하기 위한 화합물 및 이의 용도

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1041525A (en) 1964-11-11 1966-09-07 Belge Produits Chimiques Sa Benzofuran derivatives and processes for preparing the same
JPH09507071A (ja) 1993-12-21 1997-07-15 イーライ・リリー・アンド・カンパニー アミロイド原性ペプチドに関連した状態を治療又は予防する方法
SI1224175T1 (en) * 1999-10-15 2004-08-31 F. Hoffmann-La Roche Ag Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
FR2800069A1 (fr) * 1999-10-22 2001-04-27 Centre Nat Rech Scient 3-amino-2,2-di-c-alkyl-1,4-butyrolactones et 1,4- thiobutyrolactones n-substituees utiles comme stimulant de l'activite de l'acide gamma-aminobutyrique et leur procede de preparation
JP2004520347A (ja) 2001-01-15 2004-07-08 グラクソ　グループ　リミテッド Ｌｄｌ−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体
JP4307001B2 (ja) 2001-03-14 2009-08-05 キヤノン株式会社 金属配位化合物、電界発光素子及び表示装置
GB0130305D0 (en) 2001-12-19 2002-02-06 Amersham Plc Compounds for imaging alzheimers disease
US7498349B2 (en) 2002-08-02 2009-03-03 Genesoft Pharmaceuticals, Inc. Biaryl compounds having anti-infective activity
WO2004100998A2 (en) * 2003-05-07 2004-11-25 General Electric Company Compositions and methods for non-invasive imaging of soluble beta-amyloid
US20040223912A1 (en) * 2003-05-07 2004-11-11 Montalto Michael Christopher Compositions and methods for non-invasive imaging of soluble beta-amyloid
EP1644365A2 (en) 2003-07-02 2006-04-12 Biofocus Discovery Ltd Pyrazine and pyridine derivatives as rho kinase inhibitors
US7541357B2 (en) * 2004-07-15 2009-06-02 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
AU2006223070B2 (en) * 2005-03-14 2012-02-09 High Point Pharmaceuticals, Llc Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors
CN103110635A (zh) 2005-07-04 2013-05-22 海波因特制药有限责任公司 组胺h3受体拮抗剂
JP5557449B2 (ja) * 2005-10-11 2014-07-23 ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション アミロイド生成性タンパク質の造影剤としての同位体標識ベンゾフラン化合物
TW200736252A (en) * 2006-01-27 2007-10-01 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
EP2113258A1 (en) * 2006-12-05 2009-11-04 Nagasaki University Aurone derivative-containing composition for diagnosis
JP4328820B2 (ja) 2007-01-10 2009-09-09 田辺三菱製薬株式会社 医薬組成物
TW200901998A (en) * 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
US8193363B2 (en) 2008-08-29 2012-06-05 Astrazeneca Ab Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits

Also Published As

Publication number Publication date
CN102197036A (zh) 2011-09-21
ZA201102284B (en) 2012-09-26
TW201014848A (en) 2010-04-16
US8653274B2 (en) 2014-02-18
EP2328891A1 (en) 2011-06-08
WO2010024769A1 (en) 2010-03-04
AR073230A1 (es) 2010-10-20
BRPI0917147A2 (pt) 2015-11-17
ES2627769T3 (es) 2017-07-31
JP2012501324A (ja) 2012-01-19
US9309267B2 (en) 2016-04-12
UY32076A (es) 2010-03-26
CA2735497A1 (en) 2010-03-04
KR20110045023A (ko) 2011-05-03
PE20110393A1 (es) 2011-07-15
ECSP11010850A (es) 2011-03-31
BRPI0917147B1 (pt) 2020-09-15
CA2735497C (en) 2016-07-19
CO6341628A2 (es) 2011-11-21
CN102197036B (zh) 2014-12-10
AU2009286176B2 (en) 2012-04-26
JP5613669B2 (ja) 2014-10-29
EA019093B1 (ru) 2014-01-30
AU2009286176A1 (en) 2010-03-04
US20140296534A1 (en) 2014-10-02
US20100056796A1 (en) 2010-03-04
CN104447710A (zh) 2015-03-25
EA201100267A1 (ru) 2011-10-31
IL211188A0 (en) 2011-04-28
CL2011000420A1 (es) 2011-07-15
US8193363B2 (en) 2012-06-05
AR114029A2 (es) 2020-07-15
EP2328891B1 (en) 2017-04-05
US20120264943A1 (en) 2012-10-18
KR101648848B1 (ko) 2016-08-17
MX2011001918A (es) 2011-03-24
EP2328891A4 (en) 2012-07-04
CN104478862A (zh) 2015-04-01
NZ591446A (en) 2012-08-31
CN104478862B (zh) 2017-05-24

Similar Documents

Publication Publication Date Title
BRPI0917147B8 (pt) composto ou sal deste, uso de um composto ou sal deste, e, processo para fabricar um composto
UY30112A1 (es) Nuevos benzotiazoles sustitidos por heteroarilo
WO2009155017A3 (en) Novel substituted azabenzoxazoles
BR112016028345A2 (pt) composto, composição farmacêutica, métodos para inibir agregação de tau em um mamífero e para avaliar depósitos de tau em um paciente, e, uso de um composto.
BR112014012822A8 (pt) Radioligantes rotulados com flúor-18 e carbono-11 para imagiologia por tomografia por emissão de pósitrons (pet) para lrrk2
UA113186C2 (xx) Макроциклічні інгібітори lrrk2 кінази
BR122019022071B8 (pt) composto para inibição de agregação de proteínas envolvidas em doenças ligadas à agregação de proteína e/ou doenças neurodegenerativas e em depósitos de imagem de proteína agregada, uso do mesmo, e kit
BR112015025140A2 (pt) 2-fenilimidazo[1,2-a]pirimidinas como agentes de imagem
BRPI0515175A (pt) método para radiofluoração, composto, composição radiofarmacêutica, uso de um conjugado radiorrotulado ou um sal do mesmo, método para diagnose ou formação de imagem in vivo de uma doença ou condição associada com a angiogênese, e, método para monitorar o efeito do tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer
MX388479B (es) Metodos y aparatos para sintetizar agentes formadores de imagen e intermedios de estos.
MX2009007487A (es) Derivados de imidazo[1,2-a]piridina substituidos de heteroarilo novedosos.
UY30419A1 (es) Nuevos benzoxazoles heteroaril sustituidos
BRPI0808503B8 (pt) composto, uso de um composto, e, composição farmacêutica
EA201890221A1 (ru) Hbed-бисфосфонаты, их конъюгаты с радиометаллом и их применение в качестве лечебно-диагностических агентов
WO2010051196A8 (en) Novel substituted azabenzoxazoles
EA202091766A1 (ru) Композиции для диагностики для пэт-визуализации, способ получения композиции для диагностики и ее применение в диагностике
CL2011000520A1 (es) Compuestos derivados de piperazina; uso para preparar un medicamento util para tratar la enfermedad de alzheimaer, un trastorno neurodegenerativo y amiloidosis; metodo de preparacion de compuestos.
WO2010096426A3 (en) Compounds, compositions, methods of synthesis, and methods of treatment
BRPI0808090A2 (pt) Composto, composição farmacêutica, e, método in vivo para medir depósitos de amilóide em um paciente
EA201300479A1 (ru) Соединения для применения в визуализации, диагностике и/или лечении заболеваний центральной нервной системы
SG194759A1 (en) Novel precursors of glutamate derivatives
TH112395A (th) สารประกอบชนิดใหม่ที่เหมาะสมเป็นพรีเคอเซอร์ไปเป็นสารประกอบที่มีประโยชน์สำหรับการถ่ายภาพการสะสมอะมัยลอยด์
MX2025010406A (es) Aglutinantes de alfa-sinucleina y metodos de uso
MX2025009562A (es) Enlazadores de alfa-sinucleína y métodos de uso
BR112013023908A2 (pt) compostos para uso em imagens, diagnósticos e/ou tratamento de doenças do sistema nervoso central

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/08/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF